Targeting of the IL-23 Receptor to eliminate auto-reactive lymphocytes in chronic inflammatory diseases

• Unité de recherche: INNOSUISSE
• Numéro de projet: 16018.2 PFLS-LS
• Titre du projet anglais: Targeting of the IL-23 Receptor to eliminate auto-reactive lymphocytes in chronic inflammatory diseases

Description succincte (Allemand)

Targeting of the IL-23 Receptor to eliminate auto-reactive lymphocytes in chronic inflammatory diseases

Description succincte (Anglais)

Targeting of the IL-23 Receptor to eliminate auto-reactive lymphocytes in chronic inflammatory diseases

Résumé des résultats (Abstract) (Allemand)

A novel mechanism of action for the sustainable therapy of human chronic inflammatory diseases, acting|through targeted lysis of disease-driving cell, shall be investigated here. A lead molecule active in human|and non-human primates has been identified and will be developed to enable clinical testing. To support|the preclinical development a bispecific surrogate antibody fragment active in mice will be engineered and|tested in relevant mouse models for chronic inflammatory diseases to study efficacy as well as certain|safety relevant parameters.

Résumé des résultats (Abstract) (Anglais)

A novel mechanism of action for the sustainable therapy of human chronic inflammatory diseases, acting|through targeted lysis of disease-driving cell, shall be investigated here. A lead molecule active in human|and non-human primates has been identified and will be developed to enable clinical testing. To support|the preclinical development a bispecific surrogate antibody fragment active in mice will be engineered and|tested in relevant mouse models for chronic inflammatory diseases to study efficacy as well as certain|safety relevant parameters.